Rc. Bergan et al., SIMILAR CLINICAL OUTCOMES IN AFRICAN-AMERICAN AND NON-AFRICAN-AMERICAN MALES TREATED WITH SURAMIN FOR METASTATIC PROSTATE-CANCER, Journal of the National Medical Association, 89(9), 1997, pp. 622-628
African-American males have a higher incidence of prostate cancer than
non-African-American males and an overall poorer prognosis. Environme
ntal factors such as socioeconomic status and biological factors such
as an increased frequency of androgen receptor mutation have been iden
tified as causal. As androgen ablation therapy is ubiquitous in the tr
eatment of metastatic prostate cancer, little information is available
on clinical outcome independent of hormone therapy. Our experience at
the Warren G. Magnusson Clinical Center, National Institutes of Healt
h with the anticancer agent, suramin, offers the opportunity to study
clinical outcome in patients treated with an agent whose tumoricidal a
ctivity is not dependent on androgen receptor function. Clinical outco
me was examined retrospectively in 43 patients treated on a single sur
amin-based protocol and evaluated as a Function of ethnic background.
No significant difference in time to disease progression or survival w
as observed between African Americans (n=4) and the other 39 patients.
These findings are consistent with the hypothesis that therapies that
work through mechanisms independent of the androgen receptor may resu
lt in similar outcomes across ethnic groups.